NASDAQ NMS - GLOBAL MARKET · ABUS
-1.12% · -$0.0500 · Vol 2.8M
Market closed · last close 4:00 PM ET · price as of 19:09:04 ET
Arbutus Biopharma Corp

Arbutus Biopharma Corp

Biotechnology
$4.41
+ Add to watchlist
Card

Veridion Score

Refresh
Score snapshot refresh in progress
Veridion Score History · 90D

Composite trend over time

HISTORY REFRESH IN PROGRESS
REFRESHES DAILY
AI Analysis
Sovereign

Why is ABUS moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
About Arbutus Biopharma Corp
PHARMACEUTICAL PREPARATIONS
Listed since
2007
Employees
19
Country
CA

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$4.46
Day high
$4.50
Day low
$4.32
Previous close
$4.46
52W high
$4.55
-3.08% from high
52W low
$4.12
67% of range
Market cap
$881M
P/E
6.21×
EPS
$0.7100
Shares out
197.5M
Volume
2.8M
VWAP
$4.38
Price history computed in-house
1W
-3.08%
SMA 50 $4.39 · above
SMA 200 $4.39 · above
52W position 67%
Veridion warehouse edge

Warehouse intelligence for ABUS.

Veridion Score
84
0: 771: 612: 483: 904: 815: Not reported
Congress 30d
0
No recent disclosure on file.
Insider activity
See Form 4 panel below.
13F holders
None on file
Capital Web snapshots checked.
Disclosure-sourced lobbying and contract detail remains attributed in the full panels below.
Data ledger
Quote and day range
Refresh interval: 30 seconds
Source: Market data
Veridion Score
Coverage building
Source: Veridion methodology
Chart and risk context
Daily bars with no missing-bar fill
Source: Market data
News and filings
Refresh intervals shown inside each panel
Source: Market news and federal filings
Financials
Statements refresh in progress
SEC Form 4 ledger

ABUS insider activity

Arbutus Biopharma Corp

Score
Coverage building
Pressure
Mixed
Filings
0
Buys / sells
0 / 0
Net value
Not disclosed
Insiders
0
Cluster

No multi-insider buying cluster in the last 90 days

Net pressure

Mixed: Not disclosed across loaded Form 4 rows.

Convergence not established

Loaded official disclosures do not show all three sources aligned on this ticker.

Coverage building

The current Form 4 feed did not return value-bearing open-market rows for ABUS.

Source: SEC EDGAR Form 4. Rows with missing price or quantity are excluded rather than zero-filled.Methodology
Congress · 90D
Congress filing snapshot refresh in progress
Federal contracts

ABUS contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for ABUS in this window.
Lobbying spend

ABUS lobbying filings, year to date.

Registered lobbying filings matched to Arbutus Biopharma Corp.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for ABUS in this window.
Latest news · ABUS
Refresh interval: 5 minutes · Source: Market news insights
News snapshot refresh in progress
Analyst ratings
Sovereign unlock shows live analyst consensus for ABUS.
Options
Sovereign unlock shows live options positioning for ABUS.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.